High-density lipoprotein functionality in systemic lupus erythematosus

Area of Science:

• Immunology
• Cardiovascular Medicine
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease marked by inflammation, autoantibodies, and immune system overactivation.
• SLE patients exhibit premature atherosclerosis and elevated mortality, despite advancements in treatment.
• Traditional cardiovascular risk factors do not fully account for the heightened cardiovascular disease (CVD) risk in SLE.

Purpose of the Study:

• To investigate the mechanisms underlying high-density lipoprotein (HDL) dysfunction in SLE patients.
• To elucidate how inflammation in SLE alters HDL structure and function.
• To identify specific molecular changes contributing to atherogenesis in SLE.

Main Methods:

• Review of existing literature on SLE, atherosclerosis, and lipoprotein metabolism.
• Analysis of studies investigating HDL components and functions in inflammatory conditions.
• Examination of the impact of autoantibodies and immune complexes on endothelial cells and lipoproteins.

Main Results:

• Inflammation in SLE is associated with altered lipoprotein metabolism, including increased atherogenic lipoproteins (LDL, VLDL) and decreased HDL-C.
• Several factors contribute to decreased HDL levels and function in SLE, such as reduced apoA-I production, decreased LCAT activity, and increased SAA, endothelial lipase, and PLA2 activity.
• Structural and functional changes in HDL during inflammation may play a role in CVD complications observed in SLE patients.

Conclusions:

• HDL dysfunction is a significant factor contributing to the increased CVD risk in SLE patients.
• Understanding the mechanisms of HDL dysfunction in SLE is crucial for developing targeted therapies.
• Further research is needed to fully elucidate the complex interplay between SLE, inflammation, HDL, and atherosclerosis.